The abstract is read at the publisher; the summary is JClub's.
NFE2L1 is upregulated in cisplatin-resistant ovarian cancer cells and patient tissues and promotes resistance by suppressing ferroptosis, with NFE2L1 depletion resensitizing to cisplatin.
- Why it matters: Ferroptosis-based therapies are promising, but the mechanisms that regulate ferroptosis during acquired cisplatin resistance in ovarian cancer are not well defined.
- What they did: RNA sequencing identified NFE2L1 upregulation in resistant models; NFE2L1 knockdown resensitized cells to cisplatin in vitro and in vivo, and ferroptosis inhibitors largely reversed this effect. Mechanistically, NFE2L1 silencing increased SLC27A2/FATP2 transcription via direct promoter binding that inhibited SP1 recruitment, and lipidomics showed higher PUFA and lower MUFA in PE species.
- The result: By reprogramming fatty acid metabolism through the NFE2L1/SLC27A2 axis, cells became more susceptible to ferroptosis, and exogenous unsaturated fatty acids modulated NFE2L1-mediated ferroptosis sensitivity, suggesting a therapeutic route for cisplatin-resistant ovarian cancer.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.